IRIX
NASDAQIRIDEX Corporation
News · 26 weeks39+40%
2026-04-192026-10-11
Mix1790d
- Insider9(53%)
- Other3(18%)
- SEC Filings3(18%)
- Earnings2(12%)
Latest news
25 items- INSIDERSEC Form 4 filed by IRIDEX Corporation4 - IRIDEX CORP (0001006045) (Issuer)
- PRIridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced GlaucomaSAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the publication of a two-year clinical study demonstrating favorable outcomes with transscleral laser therapy (TLT) using MicroPulse® Technology (referred to as MicroPulse TLT) in patients with early, moderate, and advanced primary glaucoma. "These two-year results are particularly meaningful because they show sustained IOP reduction and reduced medication burden in patients with early-stage glaucoma, as well as in those with moderate and adva
- INSIDERSEC Form 4 filed by IRIDEX Corporation4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERSEC Form 4 filed by IRIDEX Corporation4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERSEC Form 4 filed by IRIDEX Corporation4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERSEC Form 4 filed by IRIDEX Corporation4 - IRIDEX CORP (0001006045) (Issuer)
- PRIridex Completes Relocation of Manufacturing Facility to San Jose, CaliforniaSAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced that it has completed the relocation of its manufacturing facility from Mountain View, California to a new facility in San Jose, California. "We are pleased to announce the successful relocation of our manufacturing facility. This was a key component of our plan to reduce expenses and improve profitability," said Patrick Mercer, President and CEO of Iridex. "This relocation is expected to improve operational efficiency whi
- INSIDERChief Financial Officer Dizon Romeo R bought $4,977 worth of shares (7,900 units at $0.63), increasing direct ownership by 4% to 185,306 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $1,530 worth of shares (2,354 units at $0.65), increasing direct ownership by 1% to 177,406 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $3,468 worth of shares (5,100 units at $0.68), increasing direct ownership by 3% to 175,052 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- SECIRIDEX Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - IRIDEX CORP (0001006045) (Filer)
- INSIDERChief Financial Officer Dizon Romeo R bought $4,025 worth of Commn Stock (5,368 units at $0.75) and bought $973 worth of shares (1,300 units at $0.75), increasing direct ownership by 4% to 169,952 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- SECSEC Form 10-Q filed by IRIDEX Corporation10-Q - IRIDEX CORP (0001006045) (Filer)
- SECIRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IRIDEX CORP (0001006045) (Filer)
- PRIridex Reports Second Quarter 2026 Financial ResultsMOUNTAIN VIEW, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026. Second Quarter 2026 Financial Highlights Generated total revenue of $12.6 million, compared to $13.6 million in the prior year periodCyclo G6® product family revenue was $3.9 million, representing growth of 19% year-over-year compared to $3.3 million in the prior year period Sold 17,700 Cyclo G6 probes compared to 13,100 in the prior year periodSold 18 Cyclo
- PRIridex to Report Second Quarter 2026 Financial Results on August 18, 2026MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the second quarter 2026 and provide a business update after the close of trading on August 18, 2026. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-800-715-9871 from the US or +1-646-307-1963 internationally and providing Conference I
- PRIridex Adds EndoProbe® Handpieces to EyeProGPO Product OfferingMOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its EyeProGPO product offering to include the Company’s line of EndoProbe® Handpieces. Through the agreement, more than 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Handpieces, expanding the value Iridex provides to ophthalmology practices, ambulatory surgery centers, and hospitals across the United States. The addition builds on Iridex’s existing EyeProGPO product
- SECSEC Form 8-K filed by IRIDEX Corporation8-K - IRIDEX CORP (0001006045) (Filer)
- INSIDERPresident and CEO Mercer Patrick was granted 100,000 shares, increasing direct ownership by 27% to 468,784 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R was granted 30,000 shares, increasing direct ownership by 23% to 163,284 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERLarge owner Novel Inspiration International Co., Ltd. acquired 111,997 shares (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- SECIRIDEX Corporation filed SEC Form 8-K: Other Events8-K - IRIDEX CORP (0001006045) (Filer)
- INSIDERChief Financial Officer Dizon Romeo R covered exercise/tax liability with 2,691 shares, decreasing direct ownership by 2% to 133,284 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERPresident and CEO Mercer Patrick covered exercise/tax liability with 3,990 shares, decreasing direct ownership by 1% to 368,784 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
- INSIDERChief Financial Officer Dizon Romeo R bought $1,110 worth of shares (975 units at $1.14), increasing direct ownership by 0.72% to 135,975 units (SEC Form 4)4 - IRIDEX CORP (0001006045) (Issuer)
IRIX FAQ
6 questionsWhat does IRIDEX Corporation do?
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic...Where does IRIX stock trade?
IRIDEX Corporation (IRIX) is listed on NASDAQ.What sector and industry is IRIX in?
IRIDEX Corporation operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did IRIDEX Corporation go public?
IRIDEX Corporation (IRIX) completed its IPO in 1996.What companies are similar to IRIX?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare IRIX side-by-side with any of them on Quantisnow.How can I track IRIX on Quantisnow?
Quantisnow aggregates IRIDEX Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRIX to receive live email and push alerts on every new disclosure.